<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kumar MS</submitter><funding>NCATS NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>16013</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9784173</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(24)</volume><pubmed_abstract>ALS-linked mutations induce aberrant conformations within the SOD1 protein that are thought to underlie the pathogenic mechanism of SOD1-mediated ALS. Although clinical trials are underway for gene silencing of &lt;i>SOD1&lt;/i>, these approaches reduce both wild-type and mutated forms of SOD1. Here, we sought to develop anti-SOD1 nanobodies with selectivity for mutant and misfolded forms of human SOD1 over wild-type SOD1. Characterization of two anti-SOD1 nanobodies revealed that these biologics stabilize mutant SOD1 in vitro. Further, SOD1 expression levels were enhanced and the physiological subcellular localization of mutant SOD1 was restored upon co-expression of anti-SOD1 nanobodies in immortalized cells. In human motor neurons harboring the &lt;i>SOD1 A4V&lt;/i> mutation, anti-SOD1 nanobody exp</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Anti-SOD1 Nanobodies That Stabilize Misfolded SOD1 Proteins Also Promote Neurite Outgrowth in Mutant SOD1 Human Neurons.</pubmed_title><pmcid>PMC9784173</pmcid><funding_grant_id>R01 NS108769</funding_grant_id><funding_grant_id>R01 GM137529</funding_grant_id><funding_grant_id>UL1 TR001453</funding_grant_id><funding_grant_id>R01 NS067206</funding_grant_id><funding_grant_id>R21 NS120126</funding_grant_id><funding_grant_id>R01 GM147677</funding_grant_id><funding_grant_id>R01 NS101895</funding_grant_id><funding_grant_id>R01 NS118145</funding_grant_id><pubmed_authors>Kulick D</pubmed_authors><pubmed_authors>Gadd DH</pubmed_authors><pubmed_authors>Douthwright C</pubmed_authors><pubmed_authors>Yusuf I</pubmed_authors><pubmed_authors>Kumar MS</pubmed_authors><pubmed_authors>Golebiowski D</pubmed_authors><pubmed_authors>Bosco DA</pubmed_authors><pubmed_authors>Fowler-Magaw ME</pubmed_authors><pubmed_authors>Boopathy S</pubmed_authors><pubmed_authors>Rotunno M</pubmed_authors><pubmed_authors>Sena-Esteves M</pubmed_authors><pubmed_authors>Brown RH</pubmed_authors><pubmed_authors>O'Neil AL</pubmed_authors><pubmed_authors>Xu Z</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-SOD1 Nanobodies That Stabilize Misfolded SOD1 Proteins Also Promote Neurite Outgrowth in Mutant SOD1 Human Neurons.</name><description>ALS-linked mutations induce aberrant conformations within the SOD1 protein that are thought to underlie the pathogenic mechanism of SOD1-mediated ALS. Although clinical trials are underway for gene silencing of &lt;i>SOD1&lt;/i>, these approaches reduce both wild-type and mutated forms of SOD1. Here, we sought to develop anti-SOD1 nanobodies with selectivity for mutant and misfolded forms of human SOD1 over wild-type SOD1. Characterization of two anti-SOD1 nanobodies revealed that these biologics stabilize mutant SOD1 in vitro. Further, SOD1 expression levels were enhanced and the physiological subcellular localization of mutant SOD1 was restored upon co-expression of anti-SOD1 nanobodies in immortalized cells. In human motor neurons harboring the &lt;i>SOD1 A4V&lt;/i> mutation, anti-SOD1 nanobody exp</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-04T21:55:14.655Z</modification><creation>2025-04-04T21:55:14.655Z</creation></dates><accession>S-EPMC9784173</accession><cross_references><pubmed>36555655</pubmed><doi>10.3390/ijms232416013</doi></cross_references></HashMap>